Skip to Content

Lescarden Inc LCAR

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Lescarden Inc is a biotechnology company. It is engaged in the research, testing, and development of medications for the control and cure of various diseases and the licensing of its technologies for commercialization by other companies. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. In addition, the group is also involved in the line of Catrix-based skin care products targeting the plastic surgery, dermatology and medical spa markets. Geographically, the business presence of the firm is seen in the regions of United States, Europe, and South Korea.

420 Lexington Avenue, Suite 212
New York, NY, 10170
T +1 212 687-1050
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Feb 28, 2017
Fiscal Year End May 31, 2017
Stock Type Distressed
Employees 1